Abstract: The present invention concerns photopolymerisable systems comprising reactive oligomers and/or monomers having ethylenically unsaturated groups and at least one phenylglyoxalic ester that, by photochemical decomposition, generates fragments having low migratability and low odor.

Abstract: This invention concerns photopolymerizable systems containing ethylenically unsaturated reactive oligomers and/or monomers comprising at least one photoinitiator and at least one coinitiator having low-extractability and low-volatility; the photopolymerizable systems of the invention are particularly suited for the preparation of food-packaging coatings.

Abstract: Photopolymerisable systems for coatings or photolithography comprising radically photopolimerisable oligomers and/or monomers having ethylenically unsaturated groups and, as photoinitiator, at least one compound of formula (I).

Abstract: The present invention relates to clear photopolymerisable systems for the preparation of high thickness coatings, to a procedure for their application and to the solid surfaces coated with them.

Abstract: The present invention is refereed to a white solid photoinitiator in the form of powder and consisting of 2-hydroxy-1-{4-[4-(2-hydroxy-2-methyl-propionyl)-phenoxy]-phenyl}-2-methyl-propan-1-one (COMPOUND1), and to the procedure for its preparation.

Abstract: This invention concerns photopolymerisable systems containing ethylenically unsaturated reactive oligomers and/or monomers comprising at least one photoinitiator and at least one coinitiator having low-extractability and low-volatility; the photopolymerisable systems of the invention are particularly suited for the preparation of food-packaging coatings.

Abstract: The present invention concerns photopolymerisable systems comprising reactive oligomers and/or monomers having ethylenically unsaturated groups and at least one phenylglyoxalic ester that, by photochemical decomposition, generates fragments having low migratability and low odour.

Abstract: The present invention is refereed to a white solid photoinitiator in the form of powder and consisting of 2-hydroxy-1-{4-[4-(2-hydroxy-2-methyl-propionyl)-phenoxy]-phenyl}-2-methyl-propan-1-one (COMPOUND1), and to the procedure for its preparation.

Abstract: A composition for positive heat sensitive computer-to-plate (CTP) lithographic printing plates comprising a phenolic resin and an IR absorber characterized by the fact that the composition contains from 1 to 30% w/w of an organic oxygenated phosphorous compound chosen from the group of general formula (I): wherein R1, R2, and R3 are independently a C4–C8 alkyl group or an aryl group.

Abstract: The present invention relates to clear photopolymerisable systems for the preparation of high thickness coatings, to a procedure for their application and to the solid surfaces coated with them.

Abstract: The invention relates to phenoxypropanolamines, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment of diseases that are improved by beta-3 agonist action.

Abstract: The invention relates to a composition for positive heat sensitive CTP lithographic printing plates comprising a phenolic resin and an IR absorber characterized by the fact that it contains from 1 to 30% w/w of an organic oxygenated phosphorous compound chosen from the group of general formula (I): wherein R1, R2, R3 are independently: C3-C12 linear or branched alkyl; phenyl or heteroaryl eventually substituted with R4, wherein R4 is halogen, C1-C12 linear or branched alkyl, C1-C12 linear or branched alkoxyl; OR5 wherein R5 is C3-C12 linear or branched alkyl, phenyl or heteroaryl eventually substituted with R4, wherein R4 is halogen, C1-C12 linear or branched alkyl, C1-C12 linear or branched alkoxyl.

Abstract: The invention relates to phenoxypropanolamines, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment of diseases that are improved by beta-3 agonist action.

Abstract: The present invention discloses an erythromycin derivative with antibiotic activity and pharmaceutically acceptable salts thereof, a process for their preparation and pharmaceutical compositions containing them as active principle.

Abstract: 3′-Des-dimethylamino-9-oxyimino macrolides of formula (I) endowed with anti-inflammatory activity and their pharmaceutical use are described.

Abstract: Compounds of formula (I) wherein R, R.sub.1, R.sub.2, R.sub.3 have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described. The compounds of formula (I) are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

Abstract: Compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described.The compounds of formula I are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

Abstract: Compounds of formula (I) wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described. The compounds of formula (I) are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.

Abstract: Erythromycin 9-oxime derivatives wherein a phenyl or heterocylic group is attached indirectly to the 9-position of erythromycin A through an alkylene diamine bridging member. These compounds exhibit broad spectrum antibiotic activity.

Abstract: Compounds of formula ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described.The compounds of formula I are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.